CN111116521B - 茄尼醇修饰的紫杉醇前药及其制备方法和应用 - Google Patents
茄尼醇修饰的紫杉醇前药及其制备方法和应用 Download PDFInfo
- Publication number
- CN111116521B CN111116521B CN201911264747.7A CN201911264747A CN111116521B CN 111116521 B CN111116521 B CN 111116521B CN 201911264747 A CN201911264747 A CN 201911264747A CN 111116521 B CN111116521 B CN 111116521B
- Authority
- CN
- China
- Prior art keywords
- solanesol
- prodrug
- paclitaxel
- modified
- taxol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D305/00—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms
- C07D305/14—Heterocyclic compounds containing four-membered rings having one oxygen atom as the only ring hetero atoms condensed with carbocyclic rings or ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
- A61K47/6927—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores
- A61K47/6929—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere the form being a solid microparticle having no hollow or gas-filled cores the form being a nanoparticle, e.g. an immuno-nanoparticle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Nanotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Description
Claims (5)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911264747.7A CN111116521B (zh) | 2019-12-11 | 2019-12-11 | 茄尼醇修饰的紫杉醇前药及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201911264747.7A CN111116521B (zh) | 2019-12-11 | 2019-12-11 | 茄尼醇修饰的紫杉醇前药及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN111116521A CN111116521A (zh) | 2020-05-08 |
CN111116521B true CN111116521B (zh) | 2021-11-26 |
Family
ID=70498445
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201911264747.7A Active CN111116521B (zh) | 2019-12-11 | 2019-12-11 | 茄尼醇修饰的紫杉醇前药及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111116521B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115252805A (zh) * | 2021-04-30 | 2022-11-01 | 苏州裕泰医药科技有限公司 | 卡巴他赛-脂肪醇小分子前药及其自组装纳米粒的构建 |
CN115252803A (zh) * | 2021-04-30 | 2022-11-01 | 苏州裕泰医药科技有限公司 | 多西他赛-脂肪醇小分子前药及其自组装纳米粒的构建 |
CN116332879A (zh) * | 2021-12-15 | 2023-06-27 | 沈阳药科大学 | 一种卡巴他赛前药抗肿瘤制剂 |
CN115784842A (zh) * | 2022-10-26 | 2023-03-14 | 贵州汇腾科技有限公司 | 废次烟草中高值成分茄尼醇的制备方法及应用 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106957421A (zh) * | 2017-03-31 | 2017-07-18 | 河南大学 | 一种茄尼醇衍生物、制备方法及其应用 |
CN107090082A (zh) * | 2017-04-10 | 2017-08-25 | 河南大学 | 一种具有肿瘤组织还原敏感性的茄尼醇衍生物、其制备方法和应用 |
CN108478803A (zh) * | 2018-04-08 | 2018-09-04 | 沈阳药科大学 | 氧化还原超敏感二硫键桥连前药自组装纳米粒的构建 |
-
2019
- 2019-12-11 CN CN201911264747.7A patent/CN111116521B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106957421A (zh) * | 2017-03-31 | 2017-07-18 | 河南大学 | 一种茄尼醇衍生物、制备方法及其应用 |
CN107090082A (zh) * | 2017-04-10 | 2017-08-25 | 河南大学 | 一种具有肿瘤组织还原敏感性的茄尼醇衍生物、其制备方法和应用 |
CN108478803A (zh) * | 2018-04-08 | 2018-09-04 | 沈阳药科大学 | 氧化还原超敏感二硫键桥连前药自组装纳米粒的构建 |
Non-Patent Citations (2)
Title |
---|
Solanesol derived therapeutic carriers for anticancer drug delivery;Y. Xiong, et al.;《International Journal of Pharmaceutics》;20191109;第572卷;第11823-11836页 * |
Systematic discovery of molecular probes targeting multiple nonorthosteric and spatially distinct sites in the botulinum neurotoxin subtype A (BoNT/A);S.Dadgar, W.B.Floriano;《Molecular and Cellular Probes》;20150304;第29卷;第135e143页 * |
Also Published As
Publication number | Publication date |
---|---|
CN111116521A (zh) | 2020-05-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111116521B (zh) | 茄尼醇修饰的紫杉醇前药及其制备方法和应用 | |
CN109350748B (zh) | 氧化还原双敏感键桥连小分子前药及其自组装纳米粒 | |
CN113398277B (zh) | 脂肪酸/脂肪醇-抗肿瘤物质前药及其自组装纳米粒的制备方法 | |
CN113264906B (zh) | 多西他赛二聚体小分子前药及其自组装纳米粒的构建 | |
CN108478803A (zh) | 氧化还原超敏感二硫键桥连前药自组装纳米粒的构建 | |
CN105833284A (zh) | 紫杉醇-油酸小分子前药自组装纳米粒的构建 | |
CN112604002A (zh) | 二硫键桥连的多西他赛-脂肪酸前药及其自组装纳米粒 | |
CN112089845B (zh) | 紫杉烷类药物-阿霉素前药自组装纳米粒及其应用 | |
CN110478318B (zh) | 一种芬顿试剂和阿霉素共转运靶向纳米载体及其制备方法 | |
CN112494458B (zh) | 类甘油三酯前药静注自组装纳米粒的构建 | |
CN110251685B (zh) | 紫杉醇-黄连素纳米药物的合成方法与应用 | |
CN114796513B (zh) | 二硒键桥连多西他赛二聚体前药及其自组装纳米粒 | |
CN102727905B (zh) | 一种金纳米-紫杉醇结合物及其制备方法和应用 | |
WO2017049821A1 (zh) | 水溶性多西他赛抗癌药物化合物及其制备方法和应用 | |
CN106554329B (zh) | 水溶性紫杉醇抗癌药物化合物及其制备方法和应用 | |
CN110227164B (zh) | 含酮羰基的疏水性抗肿瘤药物及其缀合物、含有缀合物的纳米制剂及其制备方法及应用 | |
CN110368500B (zh) | 一种两亲性共聚物药物前体、制备方法以及包载钙泊三醇的纳米颗粒 | |
CN107441042A (zh) | 基于硒硫键的还原响应性药物释放纳米载药胶束的制备方法 | |
CN115252805A (zh) | 卡巴他赛-脂肪醇小分子前药及其自组装纳米粒的构建 | |
KR20120126356A (ko) | 양친성 저분자량 히알루론산 복합체를 포함하는 나노 입자 및 그의 제조 방법 | |
CN116120333B (zh) | 一种鬼臼毒素纳米前药及其制备方法与应用 | |
WO2022227556A1 (zh) | 多西他赛-脂肪醇小分子前药及其自组装纳米粒的构建 | |
CN115844832A (zh) | 一种比例可调、同步释放两种原型药物的两种小分子前药的自组装纳米粒及制备方法与应用 | |
CN116327968A (zh) | 一种多西他赛前药抗肿瘤制剂 | |
CN115624631A (zh) | 一种蟾毒灵前药自组装纳米粒及其制备方法与应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information |
Inventor after: Liu Lei Inventor after: Wang Chunyun Inventor after: Song Shiyong Inventor after: Zong Lanlan Inventor after: Zhang Yanan Inventor after: Sheng Qianli Inventor after: Wang Tianshun Inventor after: Zhang Mengying Inventor after: Wang Rui Inventor before: Liu Lei Inventor before: Wang Chunyun Inventor before: Song Shiyong Inventor before: Zhang Yanan Inventor before: Sheng Qianli Inventor before: Wang Tianshun Inventor before: Zhang Mengying Inventor before: Wang Rui |
|
CB03 | Change of inventor or designer information |